in the absence of a submission from the holder of the marketing authorisation:
tocilizumab (RoActemra®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication / setting. As a result we cannot recommend its use within NHSScotland.
Download detailed advice49KB (PDF)
- Medicine name:
- tocilizumab (RoActemra®)
- SMC ID:
- treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.
- Pharmaceutical company
- BNF chapter
- Musculoskeletal and joint diseases
- Submission type
- Non submission
- Not recommended
- Date advice published
- 10 October 2016